Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Cureus ; 15(9): e46217, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37905268

ABSTRACT

BACKGROUND: Patients with unilateral peripheral vestibular deficit (UPVD) experience vertigo, dizziness, disability, negative influences on their quality of life, anxiety, and depression. In vestibular rehabilitation, virtual reality (VR) has proven to be effective. This investigation sought to evaluate the efficacy of the Balance Rehabilitation Unit (BRUTM) (MedicaaTM Montevideo, Uruguay, Balance Suite, version BRU 415) in patients with UPVD. METHODS: A prospective, randomized, controlled study involved 38 patients from the Otoneurologic Service at the National Institute of Rehabilitation "Luis Guillermo Ibarra Ibarra" in Mexico. A physician specialist diagnosed the patients with UPVD and assigned them randomly to one of two groups. Group 1 (n = 19) received traditional vestibular rehabilitation, whereas Group 2 (n = 19) received BRUTM-supported vestibular rehabilitation. Both groups were monitored by medical professionals. Patients were evaluated with the Dizziness Handicap Inventory, static and dynamic balance assessments, the dynamic gait index, and the sensory organization test. The statistical analysis was conducted using the Student's t-test, with p 0.05 considered statistically significant. RESULTS: The difference in mean age between the conventional therapy and BRUTM groups was not statistically significant. Both conventional vestibular rehabilitation and the BRUTM led to statistically significant improvements in all assessed parameters, with no statistically significant differences between the two groups. CONCLUSION: Balance, mobility, and quality of life were enhanced similarly in UPVD patients by BRUTM-supported vestibular rehabilitation and conventional vestibular rehabilitation. In addition, BRUTM facilitated patient motivation, exercise feedback, and confidence enhancement.

2.
Cureus ; 15(8): e43202, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37692741

ABSTRACT

Background Adequate nutritional support is crucial for achieving optimal growth and development in very-low-birth-weight (VLBW) preterm infants. This study evaluated the efficacy of combined nutrition (CN) (parenteral plus enteral nutrition (EN)) as an alternative nutrition protocol for VLBW infants in the neonatal intensive care unit (NICU). Methods This retrospective cohort study collected clinical and growth data from the medical records of VLBW infants weighing between 1,000 and 1,500 grams in the NICU of the Hospital of Obstetrics and Gynecology "Dr. Víctor Manuel Espinosa de los Reyes Sánchez" of the Centro Médico Nacional "La Raza" Instituto Mexicano del Seguro Social, Mexico. Parenteral nutrition (PN) alone or CN (PN plus EN) was used for nutritional management. Statistical tests, such as Student's t-test, Mann-Whitney U test, and chi-square test as appropriate, were used to compare the clinical characteristics and growth data of the two groups, and relative risk was calculated to determine the probability of comorbidities according to feeding type. Statistical significance was set at p<0.05. Results The study included 90 VLBW infants, with 27 receiving PN alone and 63 receiving CN. No statistically significant differences were found concerning sex, age, or Apgar score. The CN group showed better weight gain with statistically significant differences at 28 days (p=0.002), with no increase in the relative risk of necrotizing enterocolitis (NEC) or other complications. Conclusions The CN protocol met the caloric and nutritional needs, without increasing morbidity and mortality. The protocol had a positive impact on weight gain and a shorter NICU stay and should be considered as a nutritional alternative for VLBW infants.

3.
Molecules ; 27(19)2022 Sep 29.
Article in English | MEDLINE | ID: mdl-36234962

ABSTRACT

Cancer is a global public health problem that is related to different environmental and lifestyle factors. Although the combination of screening, prevention, and treatment of cancer has resulted in increased patient survival, conventional treatments sometimes have therapeutic limitations such as resistance to drugs or severe side effects. Oriental culture includes herbal medicine as a complementary therapy in combination with chemotherapy or radiotherapy. This study aimed to identify the bioactive ingredients in Kalanchoe pinnata, a succulent herb with ethnomedical applications for several diseases, including cancer, and reveal its anticancer mechanisms through a molecular approach. The herb contains gallic acid, caffeic acid, coumaric acid, quercetin, quercitrin, isorhamnetin, kaempferol, bersaldegenin, bryophyllin a, bryophyllin c, bryophynol, bryophyllol and bryophollone, stigmasterol, campesterol, and other elements. Its phytochemicals participate in the regulation of proliferation, apoptosis, cell migration, angiogenesis, metastasis, oxidative stress, and autophagy. They have the potential to act as epigenetic drugs by reverting the acquired epigenetic changes associated with tumor resistance to therapy-such as the promoter methylation of suppressor genes, inhibition of DNMT1 and DNMT3b activity, and HDAC regulation-through methylation, thereby regulating the expression of genes involved in the PI3K/Akt/mTOR, Nrf2/Keap1, MEK/ERK, and Wnt/ß-catenin pathways. All of the data support the use of K. pinnata as an adjuvant in cancer treatment.


Subject(s)
Kalanchoe , Coumaric Acids/analysis , Epigenesis, Genetic , Gallic Acid/analysis , Humans , Kaempferols/analysis , Kalanchoe/chemistry , Kalanchoe/genetics , Kelch-Like ECH-Associated Protein 1 , Mitogen-Activated Protein Kinase Kinases , NF-E2-Related Factor 2 , Phosphatidylinositol 3-Kinases , Plant Leaves/chemistry , Proto-Oncogene Proteins c-akt , Quercetin/pharmacology , Stigmasterol/analysis , TOR Serine-Threonine Kinases , beta Catenin
4.
J Biomech ; 135: 111035, 2022 04.
Article in English | MEDLINE | ID: mdl-35298960

ABSTRACT

Exercise encourages active and healthy aging, maintaining functional and physical capabilities. This study aimed to assess the effects of a long-term moderate aerobic exercise protocol on bone microarchitecture and fragility associated with chronic inflammation and oxidative stress in aging. Male BALB/c mice (n = 10 per group) underwent a moderate exercise protocol from 13 weeks to 27 (adulthood age) or 108 weeks of age (elderly age) and were then sacrificed. Age-match sedentary mice were included as a control group. Serum cortisol concentrations were determined by chemiluminescent immunoassay, C-reactive protein (CRP) by a turbidimetric assay, advanced glycation end-products (AGEs) and malondialdehyde (MDA) by fluorescent spectroscopy, and total glutathione (GSH) by colorimetric method. The right femur was dissected formorphometric and densitometricanalysis bycomputerized microtomography (µCT),and biomechanical properties were assessed usinga three-point bending device. Musclefrom the same extremitywas obtained to determine relative mRNA expression ofpro-inflammatory cytokines (TNF-α and IL-6) by RT-qPCR.Statistical differences were evaluated by two-way ANOVA and Holm-Sidak method post hoc with P < 0.05. In elderly mice, moderate exercise increased glutathione levels and microarchitecture complexity but decreased bone fragility and oxidative stress markers, cortisol, and pro-inflammatory cytokines. In conclusion, these results suggest a strong link between a pro-inflammatory state and age-conditioned oxidative stress on bone quality. Thus, on a human scale, moderate aerobic exercise may improve bone quality during aging.


Subject(s)
Hydrocortisone , Oxidative Stress , Animals , Cytokines/metabolism , Glutathione/metabolism , Glutathione/pharmacology , Hydrocortisone/pharmacology , Male , Mice , Mice, Inbred BALB C
5.
Adv Clin Exp Med ; 30(5): 507-515, 2021 May.
Article in English | MEDLINE | ID: mdl-33847474

ABSTRACT

BACKGROUND: Plant homeodomain finger protein 20-like 1 (PHF20L1) is a protein reader involved in epigenetic regulation that binds monomethyl-lysine. An oncogenic function has been attributed to PHF20L1 but its role in breast cancer (BC) is not clear. OBJECTIVES: To explore PHF20L1 promoter methylation and comprehensive bioinformatics analysis to improve understanding of the role of PHF20L1 in BC. MATERIAL AND METHODS: Seventy-four BC samples and 16 control samples were converted using sodium bisulfite treatment and analyzed with methylation-specific polymerase chain reaction (PCR). Bioinformatic analysis was performed in the BC dataset using The Cancer Genome Atlas (TCGA) trough data visualized and interpreted in the MEXPRESS website. Methylation, gene expression and survival evaluation were performed with R v. 4.0.2 software. Using multiple bioinformatic tools, we conducted a search for genes co-expressed with PHF20L1, analyzed its ontology and predicted associated miRNAs and miRNA-PHF20L1 networks. The expression and prognostic value of PHF20L1 and co-expressed genes were analyzed. RESULTS: We found demethylation in PHF20L1 promoter in both BC samples and healthy tissues. Data mining with 241 patients demonstrated changes in methylation of promoter regions in basal-like and luminal A subtypes. Expression of the PHF20L1 gene had a negative correlation with methylation. Twelve genes were co-expressed. PHF20L1 is a target of miR96-5p, miR9-5p and miR182-5p, which are involved in proliferation and metastasis. PHF20L1 gene expression was not associated with overall survival (OS), or relapse-free survival (RFS), but was associated with distant metastasis-free survival (DMFS). CONCLUSIONS: Our findings showed differences in methylation of PHF20L1 promoter region near TSS and upstream in BC subtypes; its overexpression impacted DMFS. We found that PHF20L1 is targeted by miR96-5p, miR9-5p and miR182-5p, which are involved in proliferation and metastasis, and regulates genes engaged in processes such as alternative splicing.


Subject(s)
Breast Neoplasms , MicroRNAs , Breast Neoplasms/genetics , Chromosomal Proteins, Non-Histone/genetics , Chromosomal Proteins, Non-Histone/metabolism , DNA Methylation , Epigenesis, Genetic , Gene Expression Regulation, Neoplastic , Humans , Methylation , MicroRNAs/genetics , MicroRNAs/metabolism , Neoplasm Recurrence, Local , Promoter Regions, Genetic
6.
Arch Med Res ; 47(8): 684-693, 2016 11.
Article in English | MEDLINE | ID: mdl-28476196

ABSTRACT

BACKGROUND AND AIMS: Occupational exposure of parents to carcinogens is of great interest in the etiology of leukemias. Evidence of the impact of such exposure on infants or small children is scarce. Here we estimated whether occupational exposure of parents to carcinogens could be a risk factor for leukemias in their children. METHODS: Cases of acute leukemia (AL) in infants ≤24 months old diagnosed in Mexico City (1998-2013) were included in a population-based, case-control study. Each of the 195 cases was matched with at least one healthy child (n = 369). For each of four exposure windows studied, the degree of exposure to carcinogens was determined for both parents by using a validated occupational exposure index. An unconditional logistic regression was carried out. RESULTS: Odds ratios (OR) and the 95% confidence intervals (CI) of the overall occupational exposure for parents during the four exposure windows indicated no association with risk of AL in their children. Pre-conception, the OR by the father 0.77 (0.49-1.21), by the mother 1.03 (0.50-2.11); during pregnancy, father 0.66 (0.38-1.15), mother 1.79 (0.46-6.90); during breastfeeding, father 0.75 (0.43-1.30), mother 0.96 (0.21-4.30); and after birth, father 0.74 (0.45-1.22), mother 0.90 (0.24-3.32). The statistical power of the sample size to identify an OR ≥2 and an exposure of ≥10% among controls was 78%. CONCLUSIONS: These data support the idea that parents' occupational exposure during any of the periods studied was not a risk factor contributing to the etiology of AL in infants ≤24 months of age.


Subject(s)
Carcinogens/toxicity , Leukemia/etiology , Occupational Exposure/adverse effects , Acute Disease , Breast Feeding , Case-Control Studies , Child, Preschool , Female , Humans , Infant , Male , Maternal Exposure/adverse effects , Mexico , Odds Ratio , Paternal Exposure/adverse effects , Pregnancy , Risk Factors , Workplace
7.
Mol Biol Rep ; 42(3): 699-704, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25387436

ABSTRACT

The FTO (fat mass and obesity-associated) gene has a strong linkage disequilibrium block, within which SNPs have been identified that are involved in the development of obesity. Recently some of these variants have also been associated with cancer. However, identification of the possible mechanisms that could explain these associations has proven to be elusive. It has been found that FTO polymorphisms can regulate the expression of genes at large kilobases of distance as well as the expression of the FTO gene itself, and regions for transcription factor binding. To date it has been observed that variants rs9939609, rs17817449, rs8050136, rs1477196, rs6499640, rs16953002, rs11075995 and rs1121980 are associated with the risk of developing cancer. Some studies have produced negative results when comparing the same polymorphisms, but make a simple association between polymorphic variants and cancer, have proved difficult because this relation is by nature multifactorial. A certain degree of variation resulting from the improper design of studies or processing of data can lead to erroneous conclusions. However, it is now unquestionable that certain FTO polymorphisms regulate genetic expression related to cancer susceptibility, although this field is just beginning to be understood.


Subject(s)
Genetic Predisposition to Disease , Neoplasms/genetics , Polymorphism, Single Nucleotide , Proteins/genetics , Alleles , Alpha-Ketoglutarate-Dependent Dioxygenase FTO , Animals , Humans , Neoplasms/etiology , Obesity/complications , Obesity/genetics , Risk
8.
Rev. esp. cardiol. (Ed. impr.) ; 65(2): 158-163, feb. 2012. tab
Article in Spanish | IBECS | ID: ibc-93983

ABSTRACT

Introducción y objetivos. México tiene alta frecuencia de la mutación 677C>T del gen de la enzima metilentetrahidrofolato reductasa. Se ha demostrado que esta mutación en estado homocigoto y la hiperhomocisteinemia se asocian a cardiopatías congénitas. Nuestro objetivo es determinar si existe dicha asociación en la población mexicana. Métodos. Se analizaron los genotipos de 60 pacientes con cardiopatías congénitas y sus madres, así como las concentraciones de homocisteína en estas, y se los comparó con los genotipos del grupo control (n = 62) y sus madres. También se compararon las combinaciones de los genotipos madre-hijo en ambos grupos. Resultados. No se encontraron diferencias significativas de las frecuencias alélicas y genotípicas entre las pacientes con cardiopatía congénita y sus controles ni en sus madres (p > 0,05). Aunque no se encontraron diferencias entre la concentración de homocisteína y la presencia del genotipo CC o TT, la tendencia fue evidente (p = 0,0621). No se encontraron diferencias significativas en las concentraciones de homocisteína dependientes de la ingesta de ácido fólico. El análisis de las diferentes combinaciones genotípicas del binomio madre-hijo entre casos y controles no mostró diferencias significativas. Conclusiones. Las frecuencias obtenidas concuerdan con las publicadas para nuestro país. No se encontraron diferencias significativas entre los grupos. Tampoco se encontró asociación de la mutación TT con hiperhomocisteinemia. No hay asociación entre las combinaciones genotípicas madre-hijo y las cardiopatías. Es necesario desarrollar estudios semejantes con un mayor número de pacientes para confirmar o descartar algunas tendencias observadas en este trabajo (AU)


Introduction and objectives. The frequency of the 677C>T mutation in the methylenetetrahydrofolate reductase gene in Mexico is one of the highest worldwide. Some studies have shown that both the homozygous state of this mutation and a high homocysteine concentration are associated with congenital heart disease. The aim of this study was to determine whether this association exists in the Mexican population. Methods. Genotypes were analyzed in 60 patients with congenital heart disease and in their mothers, and the levels of homocysteine were determined in the latter group. The genotypes were compared with those of a control group (n=62) and of their mothers. All the possible mother-child genotype combinations were also compared. Results. There were no significant differences in allele or genotype frequencies between the patients with congenital heart disease and the controls or their respective mothers (P>.05). Although no significant differences were observed when the homocysteine concentrations in the presence of the CC or the TT genotype were compared, a clear trend was observed (P=.0621). We found no significant differences in homocysteine concentrations in relation to folic acid intake. The study cases and controls did not differ in terms of the possible combinations of mother-child genotypes. Conclusions. The frequencies obtained were consistent with those reported for Mexico. No significant differences were found between groups. Nor did we find any association between TT mutations in both the mother and child and hyperhomocysteinemia. There was no evidence of an association between any of the mother-child genotype combinations and congenital heart disease. Similar studies with larger numbers of patients are required to confirm or refute some of the trends observed in this report (AU)


Subject(s)
Humans , Male , Female , Adult , Polymorphism, Genetic/physiology , Heart Defects, Congenital/genetics , Hyperhomocysteinemia/complications , Mutation/genetics , Mutation/physiology , Homocysteine/analysis , Immunoassay/methods , Immunoassay , Folic Acid/administration & dosage , Hyperhomocysteinemia/physiopathology , Hyperhomocysteinemia , Immunoassay/trends
9.
Rev Esp Cardiol (Engl Ed) ; 65(2): 158-63, 2012 Feb.
Article in English, Spanish | MEDLINE | ID: mdl-22197386

ABSTRACT

INTRODUCTION AND OBJECTIVES: The frequency of the 677C>T mutation in the methylenetetrahydrofolate reductase gene in Mexico is one of the highest worldwide. Some studies have shown that both the homozygous state of this mutation and a high homocysteine concentration are associated with congenital heart disease. The aim of this study was to determine whether this association exists in the Mexican population. METHODS: Genotypes were analyzed in 60 patients with congenital heart disease and in their mothers, and the levels of homocysteine were determined in the latter group. The genotypes were compared with those of a control group (n=62) and of their mothers. All the possible mother-child genotype combinations were also compared. RESULTS: There were no significant differences in allele or genotype frequencies between the patients with congenital heart disease and the controls or their respective mothers (P>.05). Although no significant differences were observed when the homocysteine concentrations in the presence of the CC or the TT genotype were compared, a clear trend was observed (P=.0621). We found no significant differences in homocysteine concentrations in relation to folic acid intake. The study cases and controls did not differ in terms of the possible combinations of mother-child genotypes. CONCLUSIONS: The frequencies obtained were consistent with those reported for Mexico. No significant differences were found between groups. Nor did we find any association between TT mutations in both the mother and child and hyperhomocysteinemia. There was no evidence of an association between any of the mother-child genotype combinations and congenital heart disease. Similar studies with larger numbers of patients are required to confirm or refute some of the trends observed in this report.


Subject(s)
Heart Defects, Congenital/epidemiology , Heart Defects, Congenital/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Adolescent , Adult , Alleles , Child , Child, Preschool , DNA/genetics , Female , Folic Acid/administration & dosage , Folic Acid/therapeutic use , Gene Frequency , Homocysteine/blood , Humans , Infant , Infant, Newborn , Mexico/epidemiology , Polymerase Chain Reaction , Polymorphism, Genetic , Pregnancy , Prenatal Care , Young Adult
10.
Contraception ; 84(6): 565-70, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22078184

ABSTRACT

BACKGROUND: The efficacy of contraceptives is affected by its route and ease of administration. Herein, both pharmacokinetics and pharmacodynamics of the once-a-month combined injectable contraceptive medroxyprogesterone acetate (MPA) plus estradiol cypionate (E(2)-Cyp) were compared after intramuscular (IM) or subcutaneous (SC) injection in women of reproductive age. STUDY DESIGN: Thirty women were randomly assigned to the SC (n=15) or IM (n=15) route of MPA 25 mg+E(2)-Cyp 5 mg administration. Serum samples were obtained daily for 7 days and then three times a week for 40 days in order to quantify E(2), progesterone and MPA. In addition, three ultrasounds were performed on each subject to determine follicular development, and a daily record of the bleeding pattern and side effects was maintained. RESULTS: A comparative analysis showed that the main pharmacokinetic (peak serum concentration, peak serum time, area under the serum concentration vs. time curve, absorption half-life and elimination half-life) and pharmacodynamic parameters, such as follicular development and ovulation, were similar in the SC vs. IM groups. Complete suppression in ovarian function was present in all women. The bleeding patterns and side effects were similar in both groups. CONCLUSIONS: The results presented herein demonstrate that the injection of 25 mg of MPA plus 5 mg of E(2)-Cyp has similar efficacy and safety with either the SC or IM route of administration. The SC option can be considered a viable self-administered contraceptive option that might increase women's compliance to contraceptive use.


Subject(s)
Contraceptive Agents, Female/administration & dosage , Contraceptive Agents, Female/pharmacology , Estradiol/analogs & derivatives , Medroxyprogesterone Acetate/administration & dosage , Medroxyprogesterone Acetate/pharmacology , Ovulation Inhibition/drug effects , Absorption , Adolescent , Adult , Contraceptive Agents, Female/adverse effects , Contraceptive Agents, Female/blood , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/adverse effects , Delayed-Action Preparations/pharmacokinetics , Delayed-Action Preparations/pharmacology , Drug Combinations , Estradiol/administration & dosage , Estradiol/adverse effects , Estradiol/blood , Estradiol/pharmacokinetics , Estradiol/pharmacology , Female , Half-Life , Humans , Injections, Intramuscular , Injections, Subcutaneous , Medroxyprogesterone Acetate/adverse effects , Medroxyprogesterone Acetate/blood , Menstrual Cycle/blood , Menstrual Cycle/drug effects , Oogenesis/drug effects , Ovarian Follicle/diagnostic imaging , Progesterone/blood , Ultrasonography , Young Adult
11.
Perinatol. reprod. hum ; 20(4): 98-111, oct.-dic. 2006. graf, tab
Article in Spanish | LILACS | ID: lil-632295

ABSTRACT

Alrededor del mundo existen más de 120 millones de mujeres que emplean algún tipo de anticonceptivo hormonal oral. Si bien la disminución en la dosis de los anticonceptivos orales combinados, particularmente en el contenido total de estrógenos, ha hecho que esta opción anticonceptiva, una de las más atractivas en la regulación de la fertilidad. Las usuarias, en su mayoría mujeres sanas con una baja incidencia general de enfermedades importantes, requieren de información veraz y actualizada acerca de los riesgos cardiovasculares que conllevan el empleo de estos métodos anticonceptivos. En este trabajo de revisión, se examinan estudios epidemiológicos sobre la relación entre las enfermedades cardiovasculares y el empleo de anticonceptivos hormonales orales. Específicamente, se analiza los factores de riesgo para el desarrollo de infarto agudo del miocardio, accidentes cerebrovasculares, isquémicos y hemorrágicos, así como tromboembolismo venoso. Se recomienda que antes de prescribir anticonceptivos hormonales orales a mujeres en edad reproductiva, se haga un análisis individual y profundo de los factores de riesgo asociados con su empleo.


Currently, more than 120 millions of women around the world use some method of oral hormonal contraceptive. Although the decrease in the oral contraceptive dosage, especially in total estrogen content, allowed oral contraceptives as a popular method for fertility regulation in women. Users, most of them healthy with a low incidence of chronic diseases, request information on safety of oral contraceptives regarding cardiovascular risks associated with their long-time use. In this review, we analyzed current available scientific epidemiological data on cardiovascular diseases, associated with the use of oral hormonal contraceptives, especially on its association with risk of; acute myocardial infarction, ischemic and hemorrhagic cerebrovascular diseases and venous thromboembolism. It' is advisable that before prescribing oral hormonal contraceptives to women of reproductive age, a deep individual analysis of the risk factors associated with its use should be considered.

SELECTION OF CITATIONS
SEARCH DETAIL
...